CARDURA SUMMARY
CARDURA® (doxazosin mesylate) is a quinazoline compound that is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors.
CARDURA® (doxazosin mesylate) is indicated for the following:
A. Benign Prostatic Hyperplasia (BPH)
CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double blind studies and up to 2 years in open-label studies.
B. Hypertension
CARDURA (doxazosin mesylate) is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors.
|
NEWS HIGHLIGHTSMedia Articles Related to Cardura (Doxazosin)
doxazosin mesylate, Cardura
Source: MedicineNet Benign Prostatic Hyperplasia Specialty [2009.02.20]
Title: doxazosin mesylate, Cardura
Category: Medications
Created: 12/31/1997
Last Editorial Review: 2/20/2009
Published Studies Related to Cardura (Doxazosin)
Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. [2009.08]
CONCLUSIONS: COX-2 inhibitors in combination with an alpha blocker may increase the effectiveness of the therapy for LUTS secondary to BPH without significant effects on side effect profile.
Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. [2009.03]
INTRODUCTION: Phosphodiesterase 5 inhibitors (PDE5) such as sildenafil are first-line treatment for erectile dysfunction (ED). Alpha1 (alpha1)-adrenoceptor antagonists such as doxazosin are indicated for the treatment of patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). ED and LUTS/BPH are conditions that are often associated. Accordingly, alpha1-adrenoceptor antagonists and PDE5 inhibitors will be often prescribed in real life setting together. AIM: To evaluate the effects of the combination of sildenafil and doxazosin on human cavernosal and prostatic tissue... CONCLUSIONS: Sildenafil and doxazosin reduced adrenergic tone of prostatic and cavernosal smooth muscle and their combination provided a significant benefit when targeting relaxation of both tissues. These experiments provide support for further clinical evaluation of the sildenafil and doxazosin combination in ED patients with LUTS/BPH.
Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. [2008.09]
PURPOSE: We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction... CONCLUSIONS: In patients on the doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia a single 10 mg dose of vardenafil had no symptomatic hemodynamic effects.
Effect of Vardenafil on Blood Pressure Profile of Patients With Erectile Dysfunction Concomitantly Treated With Doxazosin Gastrointestinal Therapeutic System for Benign Prostatic Hyperplasia. [2008.07.16]
PURPOSE: We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction... CONCLUSIONS: In patients on the doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia a single 10 mg dose of vardenafil had no symptomatic hemodynamic effects.
Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. [2008]
INTRODUCTION: We performed a prospective, randomized study to examine the efficacies of levofloxacin and doxazosin alone and as a combination therapy in patients with National Institutes of Health (NIH) category III chronic prostatitis/chronic pelvic pain syndrome... CONCLUSIONS: For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome. In addition, levofloxacin monotherapy was also more effective when compared with the combination therapy.
Clinical Trials Related to Cardura (Doxazosin)
The Efficacy of Doxazosin for Cocaine Users [Not yet recruiting]
Doxazosin, an alpha 1-adrenergic receptor may play an important role in cocaine addiction in
human. This study will evaluate the effectiveness of doxazosin in preventing drug relapse
among cocaine addicts.
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) [Recruiting]
OAB occurs in approximately 50% to 75% of men with BPO and up to 38% of men with BPO
continue to suffer from OAB after relief the obstruction. Symptoms of OAB are more bothersome
than the voiding complaints of slow stream and hesitancy. However, the patients with both
BPO and OAB are often not treated with muscarinic receptor antagonists due to concern that
they will experience acute urinary retention.
Tolterodine is a potent and pure muscarinic receptor antagonist that was developed
specifically for the treatment of overactive bladder. Recently, studies revealed that
tolterodine was effective, safe and well tolerated in adults with OAB and urodynamically
confirmed BPO. However, the optimal dosage of antimuscarinic for the treatment of OAB
coexisting BPO was not yet fully assessed. In real clinical situation, some patients
complain voiding difficulty after addition of antimuscarinics and want to stop
antimuscarinics. It is probable that a lower dosage of antimuscarinics combined with
alpha-adrenergic antagonists can be used safely in OAB patients with BOO, with the same
efficacy.
This study is designed to investigate the optimal doses of tolterodine SR in combination
with doxazosin in men with both BOO and OAB based on efficacy, safety, and tolerability.
Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia [Recruiting]
In this study, we investigate the changes of the expression of alpha adrenergic receptor in
the prostate tissue during 2-yr medication period in the man with benign prostatic
hyperplasia. And we also evaluate the efficacy and safety of 24 mo-treatment with doxazosin
(4mg, 8mg)
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension [Recruiting]
The purpose of this study is to investigate the efficacy and safety of Bunazosin with
Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential
hypertension accompanied by metabolic syndrome.
The Clinical Efficacy of Non-Steroidal Anti-Inflammation Drugs in Patients With Benign Prostatic Hyperplasia [Recruiting]
Non-steroidal Anti-inflammation Drugs can effectively reduce the lower urinary tract
symptoms from benign prostatic hyperplasia
|
